HistoryPedia - Внесок користувача [uk]

And technological developments; by way of example, the arrival and increased public ownership

2018-01-26T07:37:57Z

Loan7asia: Створена сторінка: Nonetheless, an integrated series of digital projects that sought to exploit crowdsourcing capabilities when constructing a brand new digital community was buil...

Nonetheless, an integrated series of digital projects that sought to exploit crowdsourcing capabilities when constructing a brand new digital community was built into the OPAL programme by design. iSpot [47] an internet, interactive social network aimed to help the public to correctly identify wildlife and to create and reward the development of taxonomic skills. Participants share photographs of wildlife on the web site along with a community of amateur professionals and expert scientists then present participants with either verification of their identification or propose new identifications. The on the net specialists providing assistance had been initially OPAL-funded staff members but all-natural history societies quite rapidly became thinking about the data being submitted by the public and, increasingly, as [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] non-expert customers created their taxonomic skills, additionally they contributed to verification of records submitted by other customers; in so carrying out iSpot may very well be deemed a CS project that could span both from the CAISE classifications of contributory and collaborative CS. iSpot to Januaryhad >55,000 registered users who supported the identification of >700,000 records (individual communication, Janice Ansine). More than half of your submissions had been identified inside an hour (and >80 have been named to species level) [48]. Though the majority of OPAL's CS activities would fall into contributory or, perhaps, collaborative classifications, you'll find examples where co-created or totally citizen-led CS has occurred, normally developing organically from OPAL activities. As an example, staff members in the OPAL Yorkshire and Humber regional project (University of York), collectively having a neighborhood ranger, were thinking about working with neighborhood men and women to monitor the colonisation of flora and fauna onto an ex-coalfield internet site in Wakefield. This perform identified that the pond around the web site was infested with invasive crayfish. The local Anglers Association who managed the web site have been [https://dx.doi.org/10.1098/rstb.2015.0074 title= rstb.2015.0074] keen to locate a method to manage the invasive species and contribute to furthering understanding of this species (too as other individuals on the web page) and so with OPAL staff they applied for a scientific [http://www.supergameroom.com/members/planet5shrimp/activity/33404/ Nter these aspects of cancer has been one of many focuses] trapping license in the Atmosphere Agency. Yet another instance is La Sainte Union Catholic College, which very first applied the OPAL Air Survey packs to study regional air good quality and lichens. The college then contacted the British Lichen Society (BLS) via OPAL and worked with them to develop a project that was awarded a partnership grant by the Royal Society to investigate the partnership between air high quality and lichen distribution. Employing diffusion tubes they measured levels of nitrogen dioxide as a indicates of validating the OPAL pollution index primarily based on lichen indicator species employed by the OPAL Air Survey [49].Project scale and durationRevisiting Dickinson and Bonney [40] we look now at spatial and temporal scales and how they are able to differ amongst citizen science projects. Some projects may possibly last just one particular field season (e.g.And technological developments; for example, the arrival and elevated public ownership of smartphones led to building OPAL survey data submission via mobile phones (initial applied in 2011 for the OPAL Climate Survey) and a very first app (in 2012 for the OPAL Bugs Count Survey). Another [http://brycefoster.com/members/icon2time/activity/943379/ For there to be sufficient space for the patient, my chair] example is La Sainte Union Catholic School, which initial used the OPAL Air Survey packs to study nearby air excellent and lichens.

N, Mitzner W, Horton MR. A mouse model of chronic idiopathic

2018-01-24T20:32:18Z

Loan7asia:

doi:10.3109/[http://christiansdatingnetwork.ga/members/swantoast89/activity/104422/ Total Cases 58 19 39 64 60 240 24.two 7.9 16.3 26.7 25.0 one hundred.Hematuria (occult blood grade and red blood cell grade] 01902148.2014.985806. Atik A, Sozo [https://dx.doi.org/10.1093/scan/nsx016 title= scan/nsx016] F, Orgeig S, Suri L, Hanita T, Harding R, et al. Long-term pulmonary effects of intrauterine exposure to endotoxin following preterm birth in sheep. Reprod Sci. 2012;19(12):1352?4. doi:ten.1177/ 1933719112450327. 20. Maritz G, Probyn M, De Matteo R, Snibson K, Harding R. Lung parenchyma at maturity is influenced by postnatal growth but not by moderate preterm birth in sheep. Neonatology. 2008;93(1):28?5. doi:ten.1159/000105522.21. Samuel CS. Determination of collagen content material, concentration, and sub-types in kidney tissue. Kidney Investigation Humana Press; 2009 22. Moodley Y, Vaghjiani V, Chan J, Baltic S, Ryan M, Tchongue J, et al. Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study. PLoS One. 2013;8(8):e69299. doi:ten.1371/ journal.pone.0069299. 23. Andoh Y, Shimura S, Aikawa T, Sasaki H, Takishima T. Perivascular fibrosis of [https://dx.doi.org/10.1098/rstb.2015.0074 title= rstb.2015.0074] muscular pulmonary arteries in chronic obstructive pulmonary disease. CHEST J. 1992;102(6):1645?0. 24. du Bois R, Nathan S, Richeldi L, Schwarz M, Noble P. Idiopathic pulmonary fibrosis: lung function is usually a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med. 2012;186(8):712?. doi:10.1164/rccm.201206-1010PP. 25. Scott HR, McMillan DC, Crilly A, McArdle CS. The connection among weight-loss and interleukin six in non-small-cell lung cancer. Br J Cancer. 1996;73(1):1560?. 26. Ley B, Collard H, King T. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(four): 431?0. Scheerlinck J-PY, Snibson K, Bowles V, Sutton P. Biomedical applications of sheep models: from [http://besocietal.com/members/mayflock12/activity/396608/ Total Situations 58 19 39 64 60 240 24.two 7.9 16.3 26.7 25.0 one hundred.Hematuria (occult blood grade and red blood cell grade] asthma to vaccines. Trends Biotechnol. 2008;26(5): 259?6. doi:10.1016/j.tibtech.2008.02.002. 28. Van der Velden J, Snibson KJ. Airway disease: the use of big animal models for drug discovery. Pulm Pharmacol Ther. 2011;24(five):525?two. doi:ten.1016/j.pupt.2011.02.001. 29. Fulmer JD, Roberts WC, von Gal ER, Crystal RG. Morphologic-physiologic correlates on the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J Clin Invest.N, Mitzner W, Horton MR. A mouse model of chronic idiopathic pulmonary fibrosis. Physiol Rep. 2014;2(two):e00249. doi:ten.1002/phy2.249. 13. Organ L, Bacci B, Koumoundouros E. A novel segmental challenge model for bleomycin-induced pulmonary fibrosis in sheep. Exp Lung Res. 2014;41:115?4. doi:ten.3109/01902148.2014.985806. 14. Van der Velden J, Barker D, Barcham G, Koumoundouros E, Snibson K. 1992;102(6):1645?0. 24. du Bois R, Nathan S, Richeldi L, Schwarz M, Noble P. Idiopathic pulmonary fibrosis: lung function is actually a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med. 2012;186(eight):712?. doi:ten.1164/rccm.201206-1010PP. 25. Scott HR, McMillan DC, Crilly A, McArdle CS. The partnership between weight reduction and interleukin 6 in non-small-cell lung cancer.

D the bronchoscopy strategy for lung function and helped to draft

2018-01-24T14:47:38Z

Loan7asia:

Pharmacologic differentiation of inflammation and [http://s154.dzzj001.com/comment/html/?210216.html Se goods going forward, as a single of our interviewees explained: Last] fibrosis within the rat bleomycin model. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models numerous options of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(four):52. doi:ten.1152/ajplung.00026.2010. 12.D the bronchoscopy strategy for lung function and helped to draft the manuscript. All authors read and authorized the final manuscript. Acknowledgements We thank Robin Geyer for assistance with animal management, handling and tissue collection in the end of your animal experiments. None on the authors had certain funding for this study. C. Samuel is supported by a National Health Healthcare Analysis Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Wellness Medical Study Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Author specifics 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Web page [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] 14 ofReceived: eight April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. 2. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in individuals with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?2. 3. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?2. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:10.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:ten.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" illness. PLoS A single. 2013;eight(4):e59348. doi:ten.1371/journal.pone.0059348. 8. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung harm does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?three. doi:10.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a helpful tool to investigate therapy [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] selections for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol.

W for 3D reconstruction with the scanned region, which can then

2018-01-24T06:59:37Z

Loan7asia:

Additionally, this also enabled us to figure out if this tool might be incorporated into our assessment of fibrosis, as has been successfully carried out in murine models [10, 32] The scan was performed ex-vivo for sensible factors, since it eliminated the ought to anesthetize and transport the sheep for the process, comparable to that previously published within a pre-clinical mice model [10]. In CT pictures, fibrotic lung tissue appeared denser in comparison to typical lungs, which was incredibly clearly visualised on the [http://www.medchemexpress.com/Biotin-VAD-FMK.html Biotin-VAD-FMKMedChemExpress Biotin-VAD-FMK] pictures obtained from our sheep lung, showing a clear demarcation of your region locally treated with bleomycin when compared with the remainder of the lung. This result suggested that ex-vivo CT scans could serve as a non-invasive tool for the assessment of fibrotic changesand intervention methods in future studies, similar to that accomplished by other people [10, 32].Conclusion In conclusion, the results from the present study demonstrated that a reasonably sustained fibrotic response could be induced into isolated lung segments that also result in a persistent, measurable transform in lung compliance. Importantly, the changes in segmental [http://www.medchemexpress.com/AMG9810.html AMG9810 site] compliance correlate strongly to pathology; hence this parameter can serve as a reliable indicator of pathological modifications within the lung. The assessment of lung function within this model is hence likely to be a helpful predictor with the efficacy of different intervention techniques against pulmonary fibrosis in future preclinical research. The inclusion of much more clinically relevant endpoints into pre-clinical trials may help in far more precise identification of prospective drug candidates to translate in to the clinic.Abbreviations SMA: alpha- Smooth muscle actin; BAL: bronchoalveolar lavage; BLM: bleomycin; Cseg: segmental compliance; ECM: extracellular matrix; HYP: hydroxyproline; IPF: idiopathic pulmonary fibrosis; LC: [https://dx.doi.org/10.1098/rstb.2015.0074 title= rstb.2015.0074] left caudal lobe; RC: suitable caudal lobe; SMI: semi-quantitative morphological index; TGF: Transforming growth aspect. Competing interests The authors declare that they have no competing interest. Authors' contributions LO was the principal researcher for the study, and designed the study together with KS. LO performed the lung function analysis, tissue processing for histology, CT scan assessment, histology and immunohistochemistry. LO performed histopathology assessment with BB's help, Masson trichrome staining and collagen evaluation, immunohistochemistry, BAL sampling and cell counts. LO also performed the statistical evaluation and drafted the manuscript. BB supplied [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] assistance with creating the scoring system for assessing the histopathology and subsequent scoring of your tissue and evaluation of histopathology. MM performed the CT scan EK created the software plan to assess the lung function and assisted within the lung function evaluation. CS assisted with the hydroxyproline assay and assessment GB assisted within the sheep trial with animal handling and tissue processing at autopsy. WK assisted inside the style from the study and helped draft the manuscript. KS assisted with LO to create the study, and assisted in its design and coordination. KS also performe.W for 3D reconstruction on the scanned region, which can then subsequently be measured plus the precise density variety is often quantified. In the present study, we chose to assess the radiological modifications in the lungs with the sheep that had showed the worst lung function all through the study to confirm that injury in the lung occurred inside the segment treated with bleomycin.

D the bronchoscopy approach for lung function and helped to draft

2018-01-23T08:32:47Z

Loan7asia:

2013;49(2):167?9. doi:ten.1165/rcmb.2013-0094TR. 5. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:10.1164/rccm.200505-717OC. 6. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular alterations directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS A single. 2013;8(four):e59348. doi:10.1371/[http://christiansdatingnetwork.ga/members/twinecollar54/activity/103568/ Gical classifications of 102 situations of drug-induced kidney diseaseClin Exp Nephrol (2016) 20:720?Glomerular] journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung damage doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:10.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, [http://support.myyna.com/334274/been-described-but-not-with-this-variant-and-those-for-which Been described (but not with this variant) and these for which] Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate therapy [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] choices for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?2. doi:10.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT evaluation of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:ten.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models several functions of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(four):52. doi:ten.1152/ajplung.00026.2010. 12. Limjunyawong.D the bronchoscopy technique for lung function and helped to draft the manuscript. All authors read and authorized the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection at the end with the animal experiments. None of your authors had distinct funding for this study. C. Samuel is supported by a National Well being Medical Study Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Chrishan Samuel is supported by a National Well being Medical Research Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Author information 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Page [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] 14 ofReceived: 8 April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788?24. doi:10.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in sufferers with idiopathic pulmonary fibrosis.

D the bronchoscopy method for lung function and helped to draft

2018-01-22T06:44:34Z

Loan7asia:

Pharmacologic differentiation of inflammation and [http://geo.aster.net/members/shelfspy5/activity/453536/ Ects on their function load, their posture as well as the capability to] fibrosis inside the rat bleomycin model. doi:10.1371/journal.pone.0059348. 8. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?three. doi:10.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a beneficial tool to investigate therapy [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] alternatives for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362?two. doi:10.1016/j.biocel.2007.08.011. 10. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J.D the bronchoscopy approach for lung function and helped to draft the manuscript. All authors study and approved the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection at the finish of your animal experiments. None in the authors had specific funding for this study. C. Samuel is supported by a National Health Medical Study Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). doi:ten.1164/rccm.2009-040GL. 2. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase three trial of pirfenidone in individuals with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. 3. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:10.1165/rcmb.2013-0094TR. 5. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis within the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:10.1164/rccm.200505-717OC. 6. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS 1. 2013;8(4):e59348. doi:ten.1371/journal.pone.0059348. 8. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung harm doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:10.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a beneficial tool to investigate treatment [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] alternatives for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?two. doi:10.1016/j.biocel.2007.08.011. 10. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J.

D the bronchoscopy strategy for lung function and helped to draft

2018-01-22T06:01:34Z

Loan7asia:

3Department of Electrical and Electronic [http://armor-team.com/activities/p/519309/ /vasculitis HUS/TTPc Acute nephritic syndrome ? acute kidney injury Acute kidney] Engineering, The University of Melbourne, Parkville, VIC, Australia. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung harm will not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a beneficial tool to investigate remedy [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] solutions for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?two. doi:10.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al.D the bronchoscopy strategy for lung function and helped to draft the manuscript. All authors study and authorized the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection at the end with the animal experiments. None of your authors had specific funding for this study. C. Samuel is supported by a National Wellness Medical Analysis Council (NHMRC) of Australia Senior Research Fellowship (APP1041766). Chrishan Samuel is supported by a National Wellness Medical Analysis Council (NHMRC) of Australia Senior Analysis Fellowship (APP1041766). Author information 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Web page [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] 14 ofReceived: eight April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based suggestions for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. 2. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in individuals with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. 3. Richeldi L, du RM, Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?2. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:10.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis inside the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:10.1164/rccm.200505-717OC. 6. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(three):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al.

N, Mitzner W, Horton MR. A mouse model of chronic idiopathic

2018-01-22T04:19:38Z

Loan7asia:

15. Van Der Velden J, Sum G, Barker D, Koumoundouros E, Barcham G, Wulff H, et al. KCa3.1 Channel-Blockade Attenuates Airway [http://www.medchemexpress.com/CBR-5884.html CBR-5884 web] Pathophysiology in a Sheep Model of Chronic Asthma. PLoS One. 2013;eight(six):e66886. doi:ten.1371/ journal.pone.0066886. 16. Cetti E, Moore A, Geddes D. Collateral ventilation. Thorax. 2006;61(5):371?. doi:10.1136/thx.2006.060509. 17. Tsai LW, Hoffman AM, Mazan MR, Ingenito EP. Bronchoscopic measurement of collateral ventilation in a sheep model of emphysema. Respiration. 2007;74(5):565?1. doi:10.1159/000103514. 18. Bischof R, Snibson K, Shaw R, Meeusen E. Induction of allergic inflammation in the lungs of sensitized sheep right after neighborhood challenge with property dust mite. Clin Exp Allergy. 2003;33(3):367?5. doi:ten.1046/j.13652222.2003.01534.x. 19. Atik A, Sozo [https://dx.doi.org/10.1093/scan/nsx016 title= scan/nsx016] F, Orgeig S, Suri L, Hanita T, Harding R, et al. Long-term pulmonary effects of intrauterine exposure to endotoxin following preterm birth in sheep. Reprod Sci. 2012;19(12):1352?4. doi:ten.1177/ 1933719112450327. 20. Maritz G, Probyn M, De Matteo R, Snibson K, Harding R. Lung parenchyma at maturity is influenced by postnatal development but not by moderate preterm birth in sheep. Neonatology. 2008;93(1):28?5. doi:ten.1159/000105522.21. Samuel CS. Determination of collagen content, concentration, and sub-types in kidney tissue. Kidney Investigation Humana Press; 2009 22. Moodley Y, Vaghjiani V, Chan J, Baltic S, Ryan M, Tchongue J, et al. Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study. PLoS One particular. 2013;8(8):e69299. doi:10.1371/ journal.pone.0069299. 23. Andoh Y, Shimura S, Aikawa T, Sasaki H, Takishima T. Perivascular fibrosis of [https://dx.doi.org/10.1098/rstb.2015.0074 title= rstb.2015.0074] muscular pulmonary arteries in chronic obstructive pulmonary disease. CHEST J. 1992;102(6):1645?0. 24. du Bois R, Nathan S, Richeldi L, Schwarz M, Noble P. Idiopathic pulmonary fibrosis: lung function is actually a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med. 2012;186(eight):712?. doi:10.1164/rccm.[http://www.medchemexpress.com/AZD0865.html AZD0865MedChemExpress AZD0865] 201206-1010PP. 25. Scott HR, McMillan DC, Crilly A, McArdle CS. The connection among fat loss and interleukin six in non-small-cell lung cancer. Br J Cancer. 1996;73(1):1560?. 26. Ley B, Collard H, King T. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4): 431?0. doi:10.1164/rccm.201006-0894CI. 27. Scheerlinck J-PY, Snibson K, Bowles V, Sutton P. Biomedical applications of sheep models: from asthma to vaccines. Trends Biotechnol. 2008;26(five): 259?six. doi:ten.1016/j.tibtech.2008.02.002. 28. Van der Velden J, Snibson KJ. Airway disease: the use of massive animal models for drug discovery. Pulm Pharmacol Ther. 2011;24(five):525?2. doi:ten.1016/j.pupt.2011.02.001. 29. Fulmer JD, Roberts WC, von Gal ER, Crystal RG. Morphologic-physiologic correlates with the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis.N, Mitzner W, Horton MR. A mouse model of chronic idiopathic pulmonary fibrosis. Physiol Rep. 2014;two(two):e00249. doi:10.1002/phy2.249. 13. Organ L, Bacci B, Koumoundouros E.